BPC-157 is not FDA approved. It has never received approval as a drug, a dietary supplement, or a food product. The FDA has gone further than simply not approving it: the agency has flagged BPC-157 as a bulk drug substance that may present significant safety risks when used in compounded medications, and it has confirmed there is no legal basis for compounding pharmacies to include it in preparations for patients.
Why the FDA Flagged BPC-157
BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a protein found in human gastric juice. It gained popularity in fitness and wellness communities for its purported healing properties, but the FDA’s position is clear: the agency lacks sufficient information to know whether BPC-157 causes harm when administered to humans.
The FDA placed BPC-157 on its list of bulk drug substances that may present significant safety risks for compounding. The agency cited three specific concerns. First, compounded drugs containing BPC-157 may trigger immune reactions (immunogenicity) depending on how they’re administered. Second, the peptide presents complexities with impurities that are difficult to characterize during manufacturing. Third, and most fundamentally, the FDA found “no, or only limited, safety-related information” for the routes of administration people are actually using, which include injection and oral consumption.
This placement effectively shut down the legal pipeline through which many people were obtaining BPC-157. Compounding pharmacies had been preparing injectable and oral formulations, but the FDA confirmed there is no legal basis for them to do so.
No Legal Way to Sell It for Human Use
The U.S. Anti-Doping Agency summarized the regulatory situation bluntly: there appears to be no legal basis for selling BPC-157 as a drug, food, or dietary supplement. The FDA has confirmed this extends to compounding pharmacies as well.
Despite this, BPC-157 remains widely available online. Many websites sell it labeled as a “research chemical” marked “not for human use,” while simultaneously providing dosing instructions and usage suggestions. This labeling is a legal workaround, not a safety assurance. Products sold this way undergo no regulatory quality checks, and their actual contents, purity, and potency are unverified. What you receive in a vial may not match what’s on the label.
For competitive athletes, BPC-157 carries an additional risk. It falls under the World Anti-Doping Agency’s prohibited substance categories, meaning its use could result in an anti-doping violation regardless of the source.
What the Animal Research Shows
The interest in BPC-157 stems from a large body of animal research, mostly conducted in rats, showing impressive tissue-healing effects. In preclinical studies, BPC-157 promotes the growth of new blood vessels, increases collagen production, and stimulates the activity of fibroblasts (the cells responsible for building connective tissue). It activates signaling pathways involved in wound repair and boosts the expression of vascular endothelial growth factor, a key protein in blood vessel formation.
The range of tissues affected in animal models is broad. Researchers have observed improved healing in muscle, tendon, ligament, bone, and gastrointestinal tissue. In rats, BPC-157 improved healing of the medial collateral ligament, protected stomach lining against damage from alcohol and anti-inflammatory drugs, and showed protective effects on the liver, pancreas, heart, and brain. Some rat studies demonstrated that it could prevent or reverse blood clots in major vessels and counteract prolonged bleeding.
These results sound remarkable, and they are, in rats. The gap between animal studies and proven human therapies is enormous. Many compounds that show dramatic effects in rodent models fail in human trials due to differences in metabolism, dosing, side effects, or simple ineffectiveness at human-relevant doses.
Where Human Evidence Stands
Only one formal human clinical trial for BPC-157 has been registered on ClinicalTrials.gov. It is a Phase 1 trial, the earliest stage of human testing, designed to evaluate basic safety and how the body processes an oral form of the peptide. The trial enrolled an estimated 42 participants, and its primary goal was simply to track adverse events, not to measure any therapeutic benefit.
Phase 1 trials are the first of at least three phases required before the FDA would consider approving a drug. Phase 2 trials test whether the drug works for a specific condition, and Phase 3 trials confirm effectiveness and monitor side effects in large groups. Even optimistically, BPC-157 is years away from the kind of evidence base that would support an FDA approval application. No pharmaceutical company has publicly announced plans to pursue full FDA approval for the peptide.
What This Means If You’re Considering BPC-157
The disconnect between BPC-157’s online reputation and its regulatory reality is stark. Social media and wellness forums are filled with personal testimonials about tendon recovery, gut healing, and injury repair. Animal studies provide a plausible biological explanation for why it might work. But “plausible” and “proven safe and effective in humans” are very different standards.
Without FDA approval or oversight, anyone using BPC-157 is taking on several unknowns: whether the product actually contains what it claims, whether the dose is accurate, whether contaminants are present, and whether the peptide behaves in a human body the way it does in a rat. The FDA’s core concern, that it simply doesn’t have enough information to know whether BPC-157 harms people, applies equally to anyone injecting or swallowing it at home. The absence of widespread reported harm is not the same as evidence of safety, especially for a substance with no systematic human safety monitoring in place.